

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the claims:

1 (Currently amended). ~~A DNA segment comprising an~~ An isolated nucleic acid, ~~wherein said nucleic acid comprises~~ comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:28; SEQ ID NO:30; SEQ ID NO:32; SEQ ID NO:34; SEQ ID NO:36; SEQ ID NO:38; SEQ ID NO:40; SEQ ID NO:42; SEQ ID NO:44; SEQ ID NO:46; SEQ ID NO:48; and SEQ ID NO:50.

2-10 (Cancelled)

11 (Currently amended). ~~A DNA segment~~ An isolated nucleic acid ~~comprising an isolated nucleic acid, said nucleic acid~~ a nucleotide sequence encoding a modified amino acid sequence of SEQ ID NO:2, wherein said modification is that amino acid 2 through amino acid 34, and amino acid 76 through amino acid 112 have been deleted.

12 (Currently amended). ~~A DNA segment~~ An isolated nucleic acid ~~comprising an isolated nucleic acid, said nucleic acid~~ a nucleotide sequence encoding a modified amino acid sequence of SEQ ID NO:2, wherein said modification is that amino acid 2 through amino acid 55, and amino acid 76 through amino acid 112 have been deleted.

13-20 (Cancelled)

21 (Currently amended). ~~A DNA segment~~ An isolated nucleic acid ~~comprising an isolated nucleic acid, a nucleotide sequence~~ which ~~nucleic acid~~ encodes a modified retinoblastoma tumor suppressor protein comprising a contiguous amino acid sequence selected from the group consisting of SEQ ID NO:29; SEQ ID NO:31; SEQ ID NO:33; SEQ ID NO:35; SEQ ID NO:37; SEQ ID NO:39; SEQ ID NO:41; SEQ ID NO:43; SEQ ID NO:45; SEQ ID NO:47; SEQ ID NO:49; and SEQ ID NO:51.

22 (Currently amended). ~~A DNA segment~~ An isolated nucleic acid ~~comprising an isolated nucleic acid, wherein said nucleic acid comprises~~ the contiguous nucleic acid sequence from between position 7 and position 2691 of SEQ ID NO:28; from between position 7 and position 2628 of SEQ ID NO:30; from between position 7 and position 2559 of SEQ ID NO:32; from between position 7 and position 2502 of SEQ ID NO:34; from between position 7 and position 2349 of SEQ ID NO:36; from between position 7 and

position 2559 of SEQ ID NO:38; from between position 7 and position 2697 of SEQ ID NO:40; from between position 7 and position 2583 of SEQ ID NO:42; from between position 7 and position 2397 of SEQ ID NO:44; from between position 7 and position 2613 of SEQ ID NO:46; from between position 7 and position 2619 of SEQ ID NO:48; or from between position 7 and position 2790 of SEQ ID NO:50.

23 (Currently amended). The ~~DNA-segment~~ nucleic acid of claim 1, 21 or 22, operationally linked under the control of a promoter.

24 (Currently amended). A recombinant vector comprising the ~~DNA-segment~~ nucleic acid of claim 23.

25 (Previously amended). The vector of claim 24 which is an adenoviral vector.

26 (Currently amended). A recombinant adenovirus comprising the ~~DNA-segment~~ nucleic acid of claim 23.

27-35 (Cancelled)

36 (Currently amended). ~~A~~ An *in vitro* recombinant host cell comprising a ~~DNA-segment~~ nucleic acid of any one of claims 1, 11, 12, 21 or 22.

37 (Original). The recombinant host cell of claim 36, wherein said host cell is a tumor cell.

38-48 (Cancelled)

49 (Currently amended). The ~~DNA-segment~~ nucleic acid of claim 1, wherein the nucleic acid ~~segment~~ comprises the nucleotide sequence of SEQ ID NO: 28.

50 (Currently amended). The ~~DNA-segment~~ nucleic acid of claim 1, wherein the nucleic acid ~~segment~~ comprises the nucleotide sequence of SEQ ID NO: 30.

51 (Currently amended). The ~~DNA-segment~~ nucleic acid of claim 1, wherein the nucleic acid ~~segment~~ comprises the nucleotide sequence of SEQ ID NO: 32.

52 (Currently amended). The ~~DNA-segment~~ nucleic acid of claim 1, wherein the nucleic acid ~~segment~~ comprises the nucleotide sequence of SEQ ID NO: 34.

53 (Currently amended). The ~~DNA-segment~~ nucleic acid of claim 1, wherein the nucleic acid ~~segment~~ comprises the nucleotide sequence of SEQ ID NO: 36.

54 (Currently amended). The ~~DNA-segment~~ nucleic acid of claim 1, wherein the nucleic acid ~~segment~~ comprises the nucleotide sequence of SEQ ID NO: 38.

55 (Currently amended). The ~~DNA-segment~~ nucleic acid of claim 1, wherein the nucleic acid ~~segment~~ comprises the nucleotide sequence of SEQ ID NO: 40.

56 (Currently amended). The ~~DNA-segment~~ nucleic acid of claim 1, wherein the nucleic acid ~~segment~~ comprises the nucleotide sequence of SEQ ID NO: 42.

57 (Currently amended). The ~~DNA-segment~~ nucleic acid of claim 1, wherein the nucleic acid ~~segment~~ comprises the nucleotide sequence of SEQ ID NO: 44.

58 (Currently amended). The ~~DNA-segment~~ nucleic acid of claim 1, wherein the nucleic acid ~~segment~~ comprises the nucleotide sequence of SEQ ID NO: 46.

59 (Currently amended). The ~~DNA-segment~~ nucleic acid of claim 1, wherein the nucleic acid ~~segment~~ comprises the nucleotide sequence of SEQ ID NO: 48.

60 (Currently amended). The ~~DNA-segment~~ nucleic acid of claim 1, wherein the nucleic acid ~~segment~~ comprises the nucleotide sequence of SEQ ID NO: 50.

61 (Currently amended). A composition comprising the ~~DNA-segments~~ nucleic acid of any one of claims 1, 11, 12, 21 or 22; and a pharmaceutically acceptable excipient.

62 (New). The recombinant host cell of claim 36, wherein said host cell is a eukaryotic cell.

63 (New). The recombinant host cell of claim 36, wherein said host cell is a human cell.